Abstract:BACKGROUND: At least three types of calcium ion channel (T, N, and L) have been recognized in nerve cells, but only the L type of channel is sensitive to drugs. Theoretically, nimodipme can lead to L-type channel inactivation and prevent calcium ion inflow, thereby exhibiting protective effects on nerve cells. OBJECTIVE: To observe the protective effects of nimodipine on glutamate-induced injury to embryonic rat neural stem cells, and to make a comparison with MK-801, a nonselective glutamate receptor antagonist. DESIGN, TIME AND SETTING: The present in vitro experiment pertaining to neural stem cells was performed at the Department of Neurology, First Hospital, Jilin University between January 2005 and December 2006. MATERIALS: Glutamate was sourced from the Shanghai Biological Research Institute of the Chinese Academy of Sciences. Nimodipine was provided by Bayer Company, Germany. Brain tissue was taken from Wistar rats on day 15 of gestation for isolation and culture of neural stem cells. METHODS: Passage 2 neural stem cell spheres were taken for preparation of single cell suspension. The prepared single cell suspension was divided into 4 groups: (1) Normal control, normally cultured. (2) Glutamate, cultured with 50, 100, 200, 500, and 1 000 mu mol/L glutamate. (3) Nimodipine, received a 30-minute nimodipine [1x(10(-8)-10(-2)) g/L] culture followed by a glutamate (200 mu mol/L) treatment step. (4) MK-801, given as 30-minute MK-801 (100 mu mol/L) culture, followed by a glutamate (200 mu mol/L) treatment Step. MAIN OUTCOME MEASURES: Determination of glutamate-induced cell death by methyl thiazolyl tetrazolium (MTT) assay; calculation of neural stem cell survival rate following addition of nimodipine. RESULTS: The survival rate of neural stem cells was approximately 25.26% following 24 hour 50 mu mol/L glutamate culture and gradually decreased as the glutamate dose increased (P < 0.05-0.01). Only 9.27% of neural stem cells survived when the glutamate dose was 1 000 mu mol/L. The survival rate of neural stem cells was significantly higher, in a dose-dependent manner, in the nimodipine [1x(10(-8)-10(-2)) g/L] group than in the glutamate group. In addition, the MK-801 group exhibited a higher survival rate after 24 hour treatment than the glutamate group (P < 0.01). CONCLUSION: Glutamate (50-1 000 mu mol/L) induces injury to neural stern cells dose-dependently. Nimodipine exhibits protective effects on injury to neural stem cells and presents the effects in a dose-dependent manner at 1x(10(-7)-10(-2)) g/L. Nimodipine displays neuroprotective effects equivalent to MK-801.

Protects Schwann Cells and Neuronal Cells from Vincristine-Induced Cell Death but Increases Tumor Cell Susceptibility

Vincristine promotes differential levels of apoptosis, mitotic catastrophe, and senescence depending on the genetic background of glioblastoma cells

Vincristine combination with Ca+2 channel blocker increase antitumor effects

Vincristine Impairs Microtubules and Causes Neurotoxicity in Cerebral Organoids

Identification of novel neuroprotectants against vincristine-induced neurotoxicity in iPSC-derived neurons

Calcium-Regulatory Proteins As Modulators of Chemotherapy in Human Neuroblastoma

Effects of glutamate and nimodipine on survival rate of embryonic rat neuronal stem cells cultured in vitro

Vincristine-Induced Neuropathy In The Rat Is Not Modified By Drug-Drug Interactions With The P-Glycoprotein Inhibitor Verapamil

Nimodipine Treatment Protects Auditory Hair Cells from Cisplatin-Induced Cell Death Accompanied by Upregulation of LMO4

Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research

Melatonin mitigates vincristine-induced peripheral neuropathy by inhibiting TNF-α/astrocytes/microglial cells activation in the spinal cord of rats, while preserving vincristine's chemotherapeutic efficacy in lymphoma cells

Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation

Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment

Disulfide Cross-Linked Micelles for the Targeted Delivery of Vincristine to B-cell Lymphoma.

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice

Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review

Bisbibenzyl Derivatives Sensitize Vincristine-Resistant KB/VCR Cells to Chemotherapeutic Agents by Retarding P-gp Activity.

C6 Ceramide Dramatically Increases Vincristine Sensitivity Both In Vivo And In Vitro, Involving Amp-Activated Protein Kinase-P53 Signaling

Impact of the Voltage-Gated Calcium Channel Antagonist Nimodipine on the Development of Oligodendrocyte Precursor Cells

Vincristine-induced peripheral neuropathy: A mini-review